Association of opioid prescribing practices with chronic pain and benzodiazepine co-prescription: a primary care data linkage study. by Torrance, N. et al.
TORRANCE, N., MANSOOR, R., WANG, H., GILBERT, S., MACFARLANE, G.J., SERPELL, M., BALDACCHINO, A., HALES, 
T.G., DONNAN, P., WYPER, G., SMITH, B.H. and COLVIN, L. 2018. Association of opioid prescribing practices with
chronic pain and benzodiazepine co-prescription: a primary care data linkage study. British journal of anaesthesia
[online], 120(6), pages 1345-1355. Available from: https://doi.org/10.1016/j.bja.2018.02.022 
Association of opioid prescribing practices with 
chronic pain and benzodiazepine co-prescription: 
a primary care data linkage study. 
TORRANCE, N., MANSOOR, R., WANG, H., GILBERT, S.,      
MACFARLANE, G.J., SERPELL, M., BALDACCHINO, A., HALES, T.G., 
DONNAN, P., WYPER, G., SMITH, B.H., COLVIN, L. 
2018 
This document was downloaded from 
https://openair.rgu.ac.uk 
This is a pre-copyedited, author-produced version of an article accepted for publication in British 
Journal of Anaesthesia following peer review. The version of record TORRANCE, N., MANSOOR, R., 
WANG, H., GILBERT, S., MACFARLANE, G.J., SERPELL, M., BALDACCHINO, A., HALES, T.G., DONNAN, P., 
WYPER, G., SMITH, B.H. and COLVIN, L. 2018. Association of opioid prescribing practices with chronic 
pain and benzodiazepine co-prescription: a primary care data linkage study. British Journal of 
Anaesthesia, 120(6), pages 1345-1355, is available online at: 
https://doi.org/10.1016/j.bja.2018.02.022.
 
 
Opioid prescribing practices, their association with chronic pain, and co-prescribing of 
benzodiazepines: a primary care data linkage study  
 
N Torrance1, R Mansoor2, H Wang1, S Gilbert3, GJ Macfarlane4, M Serpell5, A Baldacchino6, TG Hales7, P 
Donnan1, G Wyper8, *BH Smith1, *L Colvin9 
*these authors contributed equally to this paper 
1Division of Population Health Sciences, School of Medicine, University of Dundee, Dundee, DD2 4RB 
2 University of Oxford, Centre for Tropical Medicine and Global health, Nuffield Department of Medicine 
Research Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK 
3 Queensland Health, Townsville Hospital, Queensland 4814, Australia 
4 Epidemiology Group and Aberdeen Centre for Arthritis and Musculoskeletal Health, School of Medicine, 
Medical Sciences and Nutrition, University of Aberdeen, AB25 2ZD 
5 University of Glasgow, Dept of Anaesthesia, Pain Office, 3rd Floor Ambulatory Care Hospital, Stobhill, 133 
Balornock Road, Glasgow G21 3UW  
6 University of St Andrews, School of Medicine, Medical & Biological Sciences, North Haugh, St Andrews KY16 
9SU 
7 Institute of Academic Anaesthesia, Division of Neuroscience, School of Medicine, University of Dundee, DD1 
9SY  
8 Public Health and Intelligence, National Services Scotland, NHS Scotland, Meridian Court, 5 Cadogan St, 
Glasgow, G2 6QQ 
9 University of Edinburgh, Department of Anaesthesia, Critical Care and Pain Medicine, Western General 
Hospital, Edinburgh. EH4 2XU 
 
*joint senior authors 
*Correspondence to: Professor Blair H. Smith b.h.smith@dundee.ac.uk    
 
Short running title:   Opioids, co-prescribing of benzodiazepines and chronic pain: a population based study. 
 
 
Key words: prescribing, general practice, chronic pain, opioids, benzodiazepines, data linkage 
 
 
  
 
 
Abstract 
Background: Opioid prescribing is increasing worldwide with associated increases in misuse and other 
harms.  This study describes variations in national opioid prescription rates, indicators of prescribing quality, 
co-prescribing of benzodiazepines and relationship with pain severity.   
Methods: Electronic linkages of opioids prescribing: 1) national data from Information Services Division, NHS 
Scotland (2003-2012); and 2) individual data from Generation Scotland: Scottish Family Health Study.  
Descriptive analyses were conducted on national data, multi-level modelling to examine factors associated 
with variations in prescribing rates.  Chi-square tests examined associations between individual pain severity 
and opioid prescriptions.  
Results:  The number of strong opioid prescriptions more than doubled, from 474,385 in 2003 to 1,036,446 
and weak opioid prescribing increased from 3,261,547 to 4,852,583.  938,674 individuals in Scotland were 
prescribed an opioid in 2012 (18% of the population).  Patients in the most deprived areas were 3.5 times 
more likely to receive a strong opioid than patients in the least deprived.  There was significant variation in 
prescribing rates between geographical areas (<0.05), with much of this explained by deprivation.  40% of 
females aged 25-40 prescribed a strong opioid were also prescribed a benzodiazepine.  There was significant 
association between pain severity and receipt of opioid prescription (p<0.001).  Over 50% of people 
reporting severe pain were not prescribed any opioid analgesic.  
Conclusions:  This national study, using routine and individual data, found opioid prescribing in primary care 
to be common and increasing, but appearing generally appropriate in relation to pain severity.  Co-
prescribing of opioids and benzodiazepines, was common.    
 
 
  
 
 
Introduction 
There is good evidence for the efficacy of opioids in acute and cancer pain, and variable evidence of short to 
medium term efficacy in chronic non-cancer pain.1 2 There are no good long term studies of the efficacy 
opioids for patients with chronic pain. 3  Despite this, in many regions, most notably North America, western 
and central Europe, Australia and New Zealand, there is evidence of ever-increasing prescribing of opioids,3-9 
though with significant variation between countries.  Concerns have been raised about a worldwide “opioid 
epidemic” and about the potential and actual risks.10-13 The reasons for greatly-increased prescribing are 
complex and may include the wider range of opioids and routes of administration available; changes in social 
and cultural factors which encourage prescribing; and an aging population with a higher incidence of pain.  
Much of the published opioid prescribing data originates in North America, where there have been parallel 
increases in serious adverse outcomes. These include rising rates of opioid misuse and dependence and 
unintentional fatal overdose. In the USA ~63% of overdose deaths in 2015 involved a prescription opioid.10 14-
18 It is unclear how this translates to the UK and Europe, where healthcare systems differ markedly.  
 
Alongside these warnings of potential problems related to increases in opioid prescribing, reservations have 
been expressed about the effectiveness of these drugs for the long-term management of persistent painful 
conditions, such as low back pain 16 and fibromyalgia,19 especially in situations in which dose-related harms 
may outweigh benefits.20 21 The most recent European guidelines specifically recommended against their use 
for fibromyalgia.19 Systematic reviews find minor adverse events (such as nausea, constipation and 
headache) are common 22 although other serious adverse events associated with longer-term use (especially 
high doses), including prescription opioid dependence,22 impaired cognitive function,23 endocrine 
dysfunction24 and opioid-induced hyperalgesia 25 26 may occur.   
 
These serious adverse outcomes, or harms, are also associated with co-prescription of opioids with 
benzodiazepines (BZDs), as both are central nervous system and respiratory depressants and can decrease 
respiratory drive. Concurrent use is likely to put patients at greater risk of potentially fatal overdose and 
dependence, and clinicians are advised to avoid co-prescribing.3 27 
 
In primary care, prescribing of weak opioids is relatively common, with 8% of the Norwegian population 
being prescribed codeine in a single year. 28 A three-year study of new users of weak opioids, found 7% 
received a prescription at least once per year, although only 0.3% and 0.08% developed prescription 
patterns indicating “persistent” and “problematic” opioid use, respectively. 29 These findings suggest that, 
despite the high and increasing use of weak opioids in the population, the majority of patients are able to 
stop opioid treatment when their acute pain condition resolves, and challenges the perception of a high risk 
of misuse.29 30 There is also evidence that many patients with severe pain are not prescribed opioid 
analgesics and in those with persistent opioid use, strong or very strong pain is reported despite this 
treatment.30 In the context of rising rates of opioid prescribing, there is therefore conflicting evidence about 
the safety and appropriateness of prescribing for chronic pain. 
In this study we aimed to describe national opioid prescription rates, seeking socio-demographic factors 
associated with variations in these, and indicators of quality of prescribing, specifically the co-prescribing of 
BZDs. Then, to explain these at an individual level, we examined the association between receipt of opioid 
prescriptions and the presence and severity of chronic pain.  
  
 
 
METHODS 
Data sources 
National level data 
The NHS in Scotland is a publicly-funded healthcare system and is universally used by the 5.3 million 
residents.  It is administered through 14 geographical NHS Boards. In 2009, the Prescribing Information 
System (PIS) was developed as a national individual-level dataset of prescriptions issued, dispensed and 
reimbursed within the community in Scotland. 31 All prescribing data are stored securely by the Information 
Services Division (ISD), part of NHS National Services Scotland (http://www.isdscotland.org/ ).  Data held on 
each prescription include the date, strength, formulation and quantity of both generic and proprietary drugs 
that are issued. Data on reimbursed prescription items were used in this study. A full history of all 
prescription items for an individual patient are grouped using a unique NHS person identifier (Community 
Health Index (CHI) number). The CHI number can also be linked to other datasets and provides basic 
demographic information including sex, year of birth and postcode.31 
NHS Scotland spends £1.3 billion a year on medicines, with around £1 billion of the expenditure spent on 
medicines dispensed in primary care (http://www.gov.scot/Publications/2015/07/4244/8).  General 
Practitioners (GPs) account for more than 95% of community prescribing and CHI capture from prescriptions 
is high at 98.7% for GP prescribers.31 
 
We examined the ten year prescribing trends (2003-2012) for all opioid drugs across Scotland. Taking a 
snapshot of one year (2012), we analysed the rates and variations of prescribing by:  
i) the number of patients who received at least one opioid prescription during the year;  
ii) age and sex of patients;  
iii) Scottish Index of Multiple Deprivation (SIMD) for patients’ place of residence for 2012. SIMD is 
based on residential postcode and grouped into quintiles, ranking those areas from most 
deprived (ranked 1) to least deprived (ranked 5) 32 and by urban/rural classification, based on the 
Scottish Government Urban Rural Classification 
(http://www.gov.scot/Topics/Statistics/About/Methodology/UrbanRuralClassification );  
iv) all geographical NHS Board areas in Scotland (n=14);  
v) GP practices (n=1,007), which were also stratified into High, Medium and Low prescribers based 
on tertile values of the number of defined daily doses (DDDs) of opioids per day, prescribed by 
the practice.  
vi) Co-prescribing with opioids, to examine:   
a. potential for increase in serious CNS side effects due to co-prescribing of BZDs 
b. indicators of effective management of common side effects (constipation and nausea) with 
co-prescribing of laxatives and anti-emetics 
We included all individuals who received a prescription for an opioid from a GP in the period of the study.  As 
ISD data were not associated with the clinical indication for the prescribing, we were unable to exclude 
individuals for whom pain was not the main indication, or those with cancer.  
 
Individual level data – Generation Scotland: Scottish Family Health Study (GS:SFHS)  
 
 
We conducted a prescribing linkage examining the association between receipt of opioids and severity of 
chronic pain was conducted using data from Generation Scotland: Scottish Family Health Study (GS:SFHS) for 
GS participants who were residents in NHS Greater Glasgow & Clyde, NHS Fife or NHS Tayside.  GS:SFHS is a 
general population-based cohort of extended families, with detailed clinical data and DNA from 23,960 
individuals, recruited through primary care between 2006 and 2011, mainly from Tayside and Glasgow. A 
detailed description of GS:SFHS, including recruitment, data collection and baseline epidemiology, has been 
published.33 
In GS:SFHS, chronic pain was defined as reported pain or discomfort persisting longer than 3 months 34, 
completed at the time of recruitment to the study. The Chronic Pain Grade (CPG) questionnaire was used to 
assess pain severity based on intensity and pain-related disability in the previous three months.35 The CPG is 
a 7-item instrument that classifies severity into four hierarchical grades: Grade I (low disability-low 
intensity), Grade II (low disability-high intensity), Grade III (high disability-moderately limiting) and Grade IV 
(high disability-severely limiting. Clinically significant chronic pain was defined as those with CPG II-IV, 
representing those with high pain intensity and/or high pain-related disability. Therefore participants were 
categorised as “no chronic pain”, “mild” (CPG I) and “severe” chronic pain (CPG II-IV).  We stratified this 
analysis by age, sex, and potency of prescribed opioids.  
Individual GS:SFHS participants’ prescribing data were linked using CHI by the Health Informatics Centre (HIC) 
at the University of Dundee and NHS Greater Glasgow & Clyde (GGC) then pseudo-anonymised and stored in 
the HIC Safe Haven. GP prescribing for the cohort in the six months before and after their questionnaire 
submission was analysed.  
 
Prescribing data 
Prescribing data from ISD included both the number of prescription items, and the number of Defined Daily 
Doses (DDDs).  DDD is a World Health Organization standard quantitative unit of measurement defined as 
the assumed average maintenance dose per day for the medication’s main indication in adults 
http://www.whocc.no/atc_ddd_index/.  DDD was calculated by ISD analysts based on the WHO definitions.   
ISD data for 2012 by NHS Board were analysed as (i) DDDs per 1,000 population per day and (ii) prescription 
items per 1,000 population.  GS:SFHS analysis was based on the number of dispensed prescriptions.  
 
Opioids & Benzodiazepines 
Opioid drugs in Chapter 4.7.2 of the British National Formulary (BNF)36 were included, subdivided according 
to the BNF categories of “strong” and “weak” opioids with all strong opioids classified as controlled drugs in 
2012.36 Strong opioids were buprenorphine, dipipanone, fentanyl, hydromorphone, methadone, morphine, 
oxycodone, papaveretum, pentazocine, pethidine and tapentadol.  Weak opioids were codeine, 
dihydrocodeine, meptazinol and tramadol. “Combination products” such as co-codamol were categorised 
according to the strength of the parent opioid e.g. codeine.  Benzodiazepines included chlordiazepoxide, 
diazepam, loprazolam, lorazepam, lormetazepam, nitrazepam, oxazepam, temazepam. 
 
Statistical analysis 
Mainly descriptive analyses were conducted on the national level data released by ISD. Multi-level modelling 
at NHS Board level was conducted and a two-level linear regression model was used with GP practices 
 
 
nested within NHS Boards, to examine factors associated with variations in prescribing rates. The first step 
was a null model (a model with no covariates), which served as a baseline for the other models. The null 
model was used to detect how much unexplained variation stems from NHS board level. Therefore the intra-
class correlation was calculated to determine the relevance of the NHS board. The next model (Final model) 
added the effects of the SIMD quintile and urban/rural classification. For this, the outcome was number of 
DDDs per 1,000 population per year.  Negative binomial regression was performed to estimate the effect of 
age and sex on opioids prescribing rates overall.  Chi-square tests were performed to examine associations 
between categorical variables (pain severity and receipt of an opioid prescription) in the GS:SFHS linkage; 
and Kruskal-Wallis and Mann-Whitney Tests examined comparisons between the number of prescriptions in 
the three pain groups. Data were analysed using SAS, SPSS for Windows (v22) and R (v3.2.0).   
Ethics approval:  As these data are anonymised, ethical approval was not required.   
 
  
 
 
RESULTS 
National data 
Prescribing of both weak and strong opioids increased steadily over the ten year period 2003-2012.  The 
number of strong opioid prescription items more than doubled, from 474,385 in 2003 to 1,036,446 in 2012 
(Figure 1). Weak opioid prescribing increased from 3,261,547 prescription items to 4,852,583 million.  
Additional aggregate data obtained from ISD, show that the number of prescriptions continued to increase, 
with 1,206,187 strong opioid prescriptions and 5,005,405 weak opioids dispensed in 2015 (Figure 1).  
 
In 2012, 938,674 individuals in Scotland were prescribed an opioid (18% of the population) with codeine the 
most commonly prescribed drug (>658,000 individuals), followed by tramadol (>206,000). Morphine was the 
most commonly prescribed strong opioid (>40,000 people, supplementary Table 1). 
 
Sociodemographic factors 
The age and sex distributions of prescribing of weak and strong opioids are shown in Figure 2. With weak 
opioids, rates varied significantly with increasing age (p<0.001) and with gender, with higher rates of 
prescribing found among women (p<0.001).With strong opioids prescribing, rates increased significantly 
with age (p<0.001), but there was no significant difference found for gender (p=0.192).   
 
People living in the most deprived SIMD quintile were three and four times more likely to be dispensed a 
prescription for a weak or strong opioid, respectively, than patients in the least deprived areas. (Figure 2).   
NHS Boards and GP practices 
There was clear variation in prescribing rates between NHS Boards of both weak and strong opioids (Figure 
3).  There was also variation in prescribing rates between GP practices (Figure 3). The median rate of 
prescribing of strong opioids was highest in NHS Dumfries, although there was a substantial range of 
prescribing rates within, as well as between Health Boards.  
 
There was significant variation in the mean number of DDDs per 1,000 population across NHS boards 
(p<0.05). The intra-class correlation was calculated for strong (0.11) and for weak (0.27) opioids prescribing, 
indicating that 11% and 27% of total variance in these prescribing rates was due to variation between NHS 
Board areas, for strong and weak opioids respectively.  Then, after adjusting for deprivation (SIMD quintile) 
and urban/rural classification (Supplementary Table 4a b), for strong opioid prescribing the intra-class 
correlation for GP practice variance was 0.092.  This indicates that 9% of the GP practice variance in 
prescribing rates is explained by deprivation and urban/rural classification (Supplementary Table 4d). For 
weak opioids, the multilevel linear regression model identified deprivation (SIMD quintile) as a significant 
predictor (p<0.05) of number of DDDs per 1,000 population per year (Supplementary Table 4a & 4c).  After 
adjustment for deprivation, the proportion of variance of weak opioids prescribing at GP level was found to 
be 0.13, indicating that 13% of the GP level variance is explained by deprivation. 
 
Co-prescribing of opioids and benzodiazepines 
Overall co-prescribing of BZDs was more common for females than for males (Figure 4).  Almost 19% of 
females aged 30-45 years, who were prescribed a weak opioid, were also prescribed a BZD, and 38%  of 
 
 
women were co-prescribed a strong opioid and a BZD.  In younger age groups (<25 years) there were slightly 
higher rates of such co-prescribing in males compared to females.  
Co-prescriptions to manage common side effects  
With strong opioids, 50% or more of patients were co-prescribed a laxative from age 60 years, but there were 
lower rates of such co-prescribing with weak opioids (Supplementary Figure 3).  Prescribing rates of anti-
emetics were lower than of laxatives.  There was a significant difference in both age and sex (p<0.001) for all 
co-prescribing of strong and weak opioids with laxatives and anti-emetics; higher rates of co-prescribing to 
manage side effects occurred for females.   
 
Generation Scotland: Scottish Family Health Study linkage  
Data linkage was conducted for the 17,404 GS participants who had received any prescription from a GP.  We 
linked the GS:SFHS questionnaire and prescribing data of those individuals who had received a prescription 
six months before or after attending their research clinic appointment and identified 11,041 individuals who 
had also completed the chronic pain identification questions.  In total, 6,448 (58.4%) reported no chronic 
pain, 2,305 (20.9%) were classed as CPG I (mild chronic pain) and 2,288 (20.7%) as CPG II-IV (severe chronic 
pain). 
 
The characteristics and the opioids prescribing for these GS participants are shown in Table 1.  Their mean 
age was 48.3 years (SD (15.4) Range: 18 - 99 years; Median (IQR) = 50 (37 - 60) years.) and 63.7% 
(n=7,033/11,041) were women. 
 
There was a significant association between pain severity and receipt of at least one opioid prescription (chi-
squared test, p<0.001).  Almost 90% (n=5,788/6,448) of those reporting no chronic pain did not receive any 
opioid prescription and nor did 53% (n=1,215/2,288) of those who reported “severe pain”.  A weak opioid 
(and no strong opioid) was prescribed to 998 individuals (43.6%) in the severe pain group and for 338 
(14.7%), the opioid was tramadol. Only 3% who reported severe pain received a strong opioid during the six 
months before and after the clinic visit.  Benzodiazepines were co-prescribed to 9.5 % (mild pain) and 14.5% 
(severe pain) of GS:SFHS participants who also received a weak opioid, and to almost a third (29.3%) of 
individuals who reported severe chronic pain and were prescribed a strong opioid.  
 
Among the participants with severe chronic pain who received weak (n=998) or no opioid prescriptions 
(n=1,215), we also explored other commonly prescribed analgesics during the 12-month period.  Of those 
with severe pain and a weak opioid, 302 participants were prescribed a non-steroidal anti-inflammatory drug 
(NSAID), 124 were prescribed a gabapentinoid and 224 were prescribed paracetamol and so, overall, 49.4% 
(493/998) were prescribed another analgesic. Of those with severe pain and no opioid, 293 participants 
were prescribed other analgesics: 207 were prescribed an NSAID; 25 were prescribed a gabapentinoid; 115 
were prescribed paracetamol.  The remaining 50.6% (505/998) and 75.8% (922/1,215) of those with severe 
pain and weak or no opioids, respectively, were prescribed no analgesics during the six months before and 
after their report of severe chronic pain. 
 
There was a positive association between reported pain severity and the number of opioid prescriptions 
dispensed (Figure 5; Kruskal-Wallis Test: p < 0.001 and p=0.002 for weak and strong opioids respectively). 
 
 
Participants reporting mild chronic pain were dispensed more prescriptions than those without chronic pain, 
and those reporting severe chronic pain had the most frequently dispensed prescriptions.   
 
 
  
 
 
Discussion  
Using established clinical databases, we found increasing opioid prescribing over 10 years, at a national level, 
with variation by age, gender, deprivation, GP practices and NHS Board of practice location. There was 
significant variation in prescribing of both weak and strong opioids across NHS boards with much of this 
explained by deprivation.  Similar increases in opioid prescribing have been reported elsewhere in the UK 
and internationally. 4-8 
 
Overall, approximately 18% of the population received an opioid prescription in 2012 which is a higher 
proportion than reported in other countries, although similar to some figures on the prevalence of chronic 
pain [ref]. Many of these prescriptions will have been for acute pain and short-term use or at initiation of 
analgesic prescribing 37 although we are unable to determine the extent of this and were unable to link to 
clinical data nationally.  Epidemiological data from the United States and Denmark have shown that 3% to 
5% of the population use any prescribed opioids regularly for treatment of chronic pain.38-40 
 
Opioids prescribing was more common in areas of greatest deprivation, consistent with other research. 7 21 41 
42.  In a Canadian study, Gomes (2011) found that socioeconomically disadvantaged patients were prescribed 
more opioid drugs, more often, and at higher doses.  We also found that opioid prescribing generally 
increased with age and that women had higher rates than men. Chronic pain studies have consistently 
shown that more women report chronic pain than men 43 44 and that women are more likely to consult a GP 
with pain.45 There was significant variation in prescribing between NHS Boards and between GP practices; 
however, after adjusting for geographical and deprivation factors, this variance was considerably reduced.  
Similar results have been reported by Ruscitto et al (2014), suggesting both that further research is required 
to explain this association, and that any intervention to address rising opioids prescribing should look to 
incorporate relevant socio-demographic factors, rather than focusing primarily on individual GPs.  
In our work, we found co-prescribing of BZDs, particularly with strong opioids, to be relatively common 
particularly among women where up to 38% received co-prescriptions. These findings are particularly 
relevant given the recent publication of the FDA safety communication announcing serious risks and death 
associated with co-prescribing.46 It is recommended that clinicians should avoid co-prescribing opioid 
analgesic medication and benzodiazepines whenever possible. 3 36 Concurrent use of BZDs and opioids has 
been found in 31%–61% of drug-related deaths.47-49 BZDs have no clear role in analgesia, there are better 
anxiolytic therapies, and they are addictive.3 Using guidelines to address such problematic prescribing has 
the potential to optimise care and improve patient safety using evidence-based practice.17 
 
In general, we found that opioids were prescribed in relation to reported presence and severity of chronic 
pain, although with no information available about the efficacy of the prescribed opioids. We found 40% of 
those reporting severe chronic pain were not prescribed any opioids or other common analgesics in the six 
months before and after the assessment point.  These findings are consistent with data from Norway: 
among individuals reporting severe chronic pain, most did not use opioids and even among patients 
prescribed opioids, most continued to report severe pain.30 Discontinuation of opioids is common 50 and 
there are likely to be a number of factors explaining why people with severe chronic pain are not prescribed 
opioids, including: a lack of perceived efficacy or unpleasant and unacceptable physical and/or psychological 
effects.  Some patients may prefer to use other strategies to self-manage pain.51 GPs have reported difficulty 
in assessing pain levels and have concerns about lack of education/knowledge, the duration of use of strong 
opioids and possible side effects, tolerance, and addiction.52 53  These concerns may lead to the possibility 
 
 
that severe chronic pain, as reported by the GS:SFHS participants, is actually under-treated despite the 
observed increase in overall rates of opioid prescribing or indeed other analgesics.  
 
The completeness rate of ISD community pharmacy dispensed data is high, and contains all GP prescribing of 
opioids across Scotland.  This produced a large and nationally comprehensive study population, minimising 
selection bias and enabling analysis at individual, practice and NHS Board level. This is an advantage 
compared to studies that are restricted by prescription data from health insurance plans and claims data.42 54 
The analysis of the national prescribing was limited due to its aggregate format. This was necessary to 
maintain anonymity and minimise risk of potential disclosure of individual patients or prescribers, resulting 
in mainly descriptive analysis and restricting the possibility of more complex statistical analyses.  We aimed 
to explore all opioids prescribing and included methadone and buprenorphine prescribing, although we 
recognise that these are commonly used in opioid maintenance therapy.  Data from ISD lacked clinical 
details and we were unable to discern opioid prescriptions with specific diagnoses including cancer.  
Including people with cancer may inflate the overall prescribing rates, and average rates per head, for strong 
opioids as, particularly near the end of life, people with cancer may receive much higher than standard doses 
to control pain.  It would only take one or two people in a general practice being treated in this way for a few 
months to create the apparent impression of very high prescribing.  When comparing NHS boards and GP 
practices, this is likely to flatten out, and adjustment for age and deprivation will have further reduced the 
effects of this.  Other UK research has found 84% of prescriptions for strong opioids were prescribed for 
chronic non-malignant pain.{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }}  Including those without pain as the 
main indication means those receiving opioid replacement therapy for drug addiction were included – this is 
likely to have similar inflationary effects as the inclusion of those with cancer, particularly in more deprived 
areas, and areas where methadone prescribing is through GP prescribing rather than directly through 
substance misuse services.  We could not apply this information to the dataset and could therefore not 
adjust for it, though adjustment for deprivation (and age) will again have partly mitigated.  Other non-pain 
indications are likely to have much smaller effect (e.g. codeine linctus for cough, codeine for diarrhoea). 
 
Patient level data obtained from the GS:SFHS linkage included reported chronic pain severity, with a high 
rate of accurate linkage to opioids prescribing.  Overall 68% of those with any reported chronic pain were 
not prescribed an opioid, although we are unable to account for weak opioids available to buy over-the-
counter, which is likely to have resulted in an under-estimate of opioid use.  There are few studies of this 
type of linkage between prescribing data and reported pain, in a general population sample. In the study by 
Fredheim et al (2014), 85% of Norwegian patients with chronic non-malignant pain did not use opioids at all 
and in Denmark, Kurita et al (2012) reported a chronic pain prevalence of 27%, of whom, 13% were 
prescribed an opioid.   
 
The structure of the National Health Service (NHS) in the UK and the gatekeeper status of GPs means that it 
is difficult for patients to undertake “doctor-shopping” and obtain prescriptions from multiple prescribers, as 
is possible in other countries.10 55 Given this GP gatekeeper role, our interpretation is that the high rates of 
use of opioids and the extent of misuse that now exists in countries such as North America should not be 
seen as a ubiquitous problem.  Opioids, particularly strong opioids are also used much less frequently in 
many European countries4 16 including Portugal 40, Norway 30 and Denmark 38 than in US.  Long term or high 
levels of prescribing of opioids for pain should only be after full assessment and in conjunction with a 
specialist, according to latest guidelines 56-58 and with co-prescribing of BZDs avoided.  Caution is required 
when prescribing opioids, or any medicine, long-term for chronic pain, in view of the potential harms. The 
 
 
Royal College of Anaesthetists highlights this, with approaches to managing risks and benefits, and 
emphasises the need to adopt a biopsychosocial approach to managing chronic pain. 57 
 
Future research  
Evidence on long-term opioid therapy for chronic pain is limited but suggests an increased risk of serious 
harms that appears to be dose-dependent.59 More research is needed to identify factors associated with 
clinical indications for increases in prescribing, and subsequent problem-use following prescription in 
primary care, with a view to identifying these and preventing misuse and related outcomes. This is likely to 
benefit patient safety, high risk prescribing and polypharmacy programmes. Further research is also needed 
to establish the long term efficacy of opioids, as it is not possible to ascertain this from the current evidence. 
Conclusions 
This national study, using routine and individuals’ data, found opioid prescribing in primary care to be 
common and increasing. Patients prescribed a strong opioid were likely to have severe pain, which may 
indicate appropriate prescribing to attempt to manage this pain. There were, also a considerable number of 
patients with severe pain not prescribed an opioid, or other analgesics.  The appropriateness, or otherwise 
of this is difficult to define with current data, but may represent under-prescribing of opioids when 
indicated. This highlights the importance of guidance for prescribing safely and effectively, 3 56 58 the need to 
establish protocols for appropriate person-centred prescribing and for the continued development of 
alternative interventions that may be more effective and safer than long-term opioids in chronic painful 
conditions.  Chronic painful conditions present by far the most prevalent causes of disability in the Global 
Burden of Disease Report 60 and it is important that we are equipped to address this with better public and 
professional understanding of chronic pain prevention and management as well as appropriate, safe and 
effective prescribing of opioids. 
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Table 1.  Characteristics of the GS:SFHS participants and their receipt of an opioid prescription within six 
months before and/or after self-reported pain, n (%)  
 No Chronic Pain  Mild pain Severe pain Total (%) 
Gender     
 Female 3,989 (61.9) 1,401 (60.8) 1,643 (71.8) 7,033 (63.7) 
 Male 2,459 (38.1) 904 (39.2) 645 (28.2) 4,008 (36.3) 
 Total (%) 6,448 (58.4) 2,305 (20.9) 2,288 (20.7) 11,041 (100) 
Age     
 <25 years 795 (12.3) 94 (4.1) 104 (4.5) 993 (9.0) 
 25-44 years 2,141 (33.2) 609 (26.4) 574 (25.1) 3,324 (30.1) 
 45-64 years 2,766 (42.9) 1,252 (54.3) 1,268 (55.4)( 5,286 (47.9) 
 65+ years 746 (11.7) 350 (15.2) 342 (14.9) 1,438 (13.0) 
No opioid 5,788 (89.8) 1,927 (83.6) 1,215 (53.1) 8,959 (81.1) 
Weak opioid 639 (9.9) 368 (16.0) 998 (43.6) 1,976 (17.9) 
Strong opioid 21 (0.3) 10 (0.4) 75 (3.3) 106 (1.0) 
Co-prescribing with BZDs     
          Weak opioid & BZD** 57 (8.9) 35 (9.5) 149 (14.9) 241 (12.2) 
          Strong opioid & BZD** 1 (4.5) 0 22 (29.3) 23 (21.7) 
 
Notes: Mild pain = Chronic Pain Grade (CPG) I; Severe pain = CPG II-IV; Strong opioids prescribing includes methadone & buprenorphine 
which are often prescribed for substance misuse replacement therapy. There were a total on 81 individuals prescribed these drugs (12 
with no pain; 3 with mild pain and 10 with severe pain). **% of GS participants co-prescribed a BZD within pain and opioid group 
 
  
 Figure 1. Trends in opioids prescribing in Scotland (2003-2012) 
 
 Figure 2. Opioids prescribing and sociodemographic characteristics (age & sex; Scottish Index of Multiple Deprivation) 
 
 Figure 3. Opioids by NHS board of GP prescriber for 2012 
 Figure 4. Co-prescribing of opioids with benzodiazepines 
 
 Figure 5. Boxplots for number of prescriptions by pain severity group for weak/strong opioids 
Weak opioid prescriptions: The number of prescriptions in the 3 groups are significantly different Kruskal-Wallis Test: p < 0.001. 
Pairwise comparisons (Mann-Whitney test) No pain v Mild pain (p <0.001); No pain v Severe pain (p<0.01) and Mild vs. Severe pain (p 
<0.001) The patients with mild chronic pain had more frequent prescription of than those without chronic pain, where those with 
severe chronic pain had the most frequent weak opioid prescription. 
Strong opioid prescriptions: The number of prescriptions in the 3 groups are significantly different Kruskal-Wallis Test: p = 0.002. 
Pairwise comparisons (Mann-Whitney test) for prescriptions of strong opioids found no significant difference for No pain v Mild pain 
(p =0.621). There were significantly more prescriptions for No pain v Severe pain (p=0.004) and Mild vs. Severe pain (p=0.022). 
Methadone (M) and Buprenorphine (BT) were excluded from this analysis, as these are most commonly prescribed for managing 
substance misuse. 
Supplementary Tables & Figures 
 
Table 1.  Number of patients by individual drug for calendar year 2012 
Potency Classification Drug Name Number of patients 
Strong Opioids Morphine 40,146 
 Methadone 17,590 
 Oxycodone 14,066 
 Fentanyl 11,805 
 Buprenorphine 11,395 
  Diamorphine  3,177 
 Pethidine  1,186 
 Tapentadol 395 
  Dipipanone 299 
  Hydromorphone 287 
  Pentazocine 79 
  Papaveratum 3 
Weak Opioids* Codeine  658,000 
 Tramadol  206,618 
  Dihydrocodeine 170,133 
  Meptazinol 2,255 
*Includes combination products 
 
  
URBAN/ RURAL Classification  
Urban/Rural 2012/12 classification 
1 - Large Urban Areas - Settlements of over 125,000 people 
2 - Other Urban Areas - Settlements of 10,000 to 125,000 people 
3 - Accessible Small Towns - Settlements of between 3,000 and 10,000 people and within 30 minutes’ drive of a settlement of 10,000 or more. 
4 - Remote Small Towns - Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more 
5 - Very Remote Small Towns - Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to settlement of 10,000 or more 
6 - Accessible Rural - Settlements of less than 3,000 people and within 30 minutes’ drive of a settlement of 10,000 or more 
7 - Remote Rural - Settlements of less than 3,000 people and with a drive time of between 30 and 60 minutes to a settlement of 10,000 or more 
8 - Very Remote Rural - Settlements of less than 3,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more 
 
 
 
           
 
Supplementary Figure 1. Urban/ rural classification for Strong and Weak opioids 
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 Supplementary Table 2.  Opioids prescribing by NHS Board for 2012 
  STRONG WEAK 
NHS board of 
prescriber 
Population No. of prescription 
items per 1,000 
population 
No. of DDDs per 
1,000 popn per year 
No. of prescription 
items per 1,000 
population 
No. of DDDs per 
1,000 popn per year 
Ayrshire & Arran 373,189 150.6 2,392.90 1,231 24,149 
Borders 113,707 154.5 2,064.70 788 14,517 
Dumfries & Galloway 150,828 271.6 4,994.10 1,027 18,095 
Fife 366,219 144.7 2,914.60 894 20,589 
Forth Valley 299,099 149.6 2,182.00 965 19,976 
Grampian 573,420 163.3 4,133.20 617 12,071 
Greater Glasgow & Clyde 1,217,025 273.2 7,524.70 1,076 21,269 
Highland 319,811 176.5 2,991.90 772 14,002 
Lanarkshire 572,520 238.6 4,896.00 1,186 24,292 
Lothian 843,733 146.5 5,296.10 679 15,628 
Orkney 21,530 102.4 1,194.40 548 9,251 
Shetland 23,210 210.4 4,334.40 547 9,432 
Tayside 411,749 159.4 2,620.10 776 16,869 
Western Isles 27,560 253.4 3,317.30 849 15,046 
 
 
 
Table 3. Tertiles of GP prescribing for STRONG opioids by NHS Board (2012) 
 
NHS_board  Tertiles of prescribing 
Total No. of 
GP practices 
HIGH 
n (%) 
MEDIUM 
n (%) 
LOW 
n (%) 
Ayrshire & Arran 57 12 (21.1) 23 (40.43) 22 (38.6) 
Borders 23 2 (8.7) 9 (39.1) 12 (52.2) 
Dumfries & Galloway 34 26 (76.5) 5 (14.7) 3 (8.8) 
Fife 58 15 (25.9) 23 (39.7) 20 (34.5) 
Forth Valley 56 8 (14.3) 19 (33.9) 29 (51.8) 
Grampian 79 30 (38.0) 24 (30.4) 25 (31.7) 
Greater Glasgow & Clyde 269 118 (43.9) 66 (24.5) 85 (31.6) 
Highland 101 23 (22.8) 41 (40.6) 37 (36.6) 
Lanarkshire 100 9 (9.0) 49 (49.0) 42 (42.0) 
Lothian 124 66 (52.8) 30 (24.0) 29 (23.2) 
Orkney 14 1 (7.1) 2 (14.3) 11 (78.6) 
Shetland 10 2 (20.0) 4 (40.0) 4 (40.0) 
Tayside 67 14 (20.9) 38 (56.7) 15 (22.4) 
Western Isles 10 6 (60.0) 3 (30.0) 1 (10.0) 
TOTAL 1002 332 (33.1) 336 (33.5) 335 (33.4) 
Note:  3 practices identified by ISD as “specialist services practices” are not included in the GP practice level analysis, one each from Grampian, Greater Glasgow & C and 
Lothian. One Highland practice did not prescribe any strong opioids  
 
 
Supplementary Figure 2.  Percentage of GP practices in tertiles of prescribing of STRONG opioids by NHS Board (2012) 
 
  
Supplementary Table 4a:  Linear univariable and multivariable analysis by strong and weak opioids with Number of DDDs per 1000 population per year as 
dependent variable  
 Univariable model Multivariable model (Final model ) 
 Strong Opioids Weak  Opioids Strong Opioids Weak  Opioids 
Parameter Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value  P-value 
     Intercept 7.24 (7.00- 7.47) < 0.001 9.32 (9.17- 9.48) < 0.001 7.35 (7.11- 7.60) < 0.001 9.32 (9.17- 9.48) < 0.001 
SIMD.quintile                 1 0.82 (0.63-1.00) < 0.001 0.54 (0.45- 0.63) < 0.001 0.85 (0.66-1.03) < 0.001 0.54 (0.45- 0.63) < 0.001 
                                        2 0.61 (0.43- 0.80) < 0.001 0.38 (0.29- 0.47) < 0.001 0.69 (0.50- 0.88) < 0.001 0.38 (0.29- 0.47) < 0.001 
                                        3 0.38 (0.19- 0.57) < 0.001 0.21 (0.12- 0.31) < 0.001 0.46 (0.26- 0.66) < 0.001 0.21 (0.12- 0.31) < 0.001 
                                        4 0.34 (0.14- 0.53) < 0.001 0.17 (0.08- 0.27) < 0.001 0.40 (0.21- 0.60) < 0.001 0.17 (0.08- 0.27) < 0.001 
                                        5 Reference group  Reference group  Reference group    
   Intercept 7.84 (7.63- 8.04) < 0.001 9.56 (9.40- 9.72) < 0.001     
Urban / Rural                      8 -0.29 (-0.58- -0.00) 0.054 0.01 (-0.15- 0.16) 0.910 -0.29 (-0.58- 0.00) 0.051   
                                       7 -0.23 (-0.54- 0.07) 0.133 0.04 (-0.11- 0.20) 0.577 -0.21 (-0.51- 0.08) 0.154   
                                      6 -0.31(-0.54- -0.07) 0.012 -0.02 (-0.14- 0.10) 0.721 -0.29 (-0.52- -0.06)  0.014   
                                      5 0.43 (-0.11- 0.98) 0.119 0.25 (-0.03- 0.54) 0.082 0.35 (-0.17- 0.88) 0.190   
                                     4 0.08 (-0.25- 0.41) 0.641 0.06 (-0.11- 0.23) 0.467 -0.01 (-0.33- 0.31) 0.949   
                                     3 -0.30 (-0.52- -0.08) 0.007 0.00 (-0.12 - 0.11) 0.944 -0.35 (-0.56- -0.14) < 0.001   
                                    2 -0.12 (-0.27- 0.04) 0.138 0.11 (0.03- 0.19) 0.005 -0.24 (-0.4- -0.09) 0.002   
                                    1 Reference group  Reference group  Reference group    
 
 
 
Supplementary Table 4b Strong Opioids  
Sum Sq Mean Sq Numerator DF Denominator DF F.value Pr(>F) 
SIMD.quintile 63.091 15.7728 4 983.43 21.9815 < 2.2e-16 
UR8 16.547 2.3638 7 912.1 3.2943 0.001821 
 
 
Supplementary Table 4c  Weak Opioids  
Sum Sq Mean Sq Numerator DF Denominator DF F.value Pr(>F) 
SIMD.quintile 28.576 7.1439 4 989.12 40.027 < 2.2e-16 
 
 
Supplementary Table 4d: Variance Components for two Two-level Models 
     Strong Opioids     Weak Opioids 
Variance Components       Null model  
       estimates 
Final model   
 estimates 
      Null model        
       estimates 
Final model   
 estimates 
Level - 2/ NHS board 0.094 0.111 0.075 0.063 
Level- 1 Residual 0.791 0.718 0.206 0.178 
 
 
  
  
 
    
        
 
Supplementary Figure 3. Co-prescribing to manage side-effects 
 
